The offering, which is expected to close around July 16, 2026, includes 6,027,399 shares of common stock and 4,931,506 pre-funded warrants. Underwriters have also been granted a 30-day option to purchase an additional 1,643,835 shares. Morgan Stanley, Jefferies, and Cantor Fitzgerald are leading the book-running process for the capital raise.

Q32 Bio plans to deploy the net proceeds toward general working capital and the advancement of bempikibart, an anti-IL-7Rα antibody currently in Phase 2 trials for alopecia areata. This autoimmune condition affects roughly 700,000 people in the United States, representing a significant area of focus for the company’s clinical strategy. The securities were issued under a shelf registration statement declared effective by the SEC on July 13.